Search

Your search keyword '"Yamaguchi, Kensei"' showing total 1,266 results
Start Over Author "Yamaguchi, Kensei"
1,266 results on '"Yamaguchi, Kensei"'

51. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Author

Shitara, Kohei, primary, Bang, Yung-Jue, additional, Iwasa, Satoru, additional, Sugimoto, Naotoshi, additional, Ryu, Min-Hee, additional, Sakai, Daisuke, additional, Chung, Hyun Cheol, additional, Kawakami, Hisato, additional, Yabusaki, Hiroshi, additional, Sakamoto, Yasuhiro, additional, Nishina, Tomohiro, additional, Inaki, Koichiro, additional, Kuwahara, Yusuke, additional, Wada, Naoya, additional, Suto, Fumitaka, additional, Arita, Takeo, additional, Sugihara, Masahiro, additional, Tsuchihashi, Zenta, additional, Saito, Kaku, additional, Kojima, Akihito, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

53. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer

Author

Lee, Jin, primary, Mashima, Tetsuo, additional, Kawata, Naomi, additional, Yamamoto, Noriko, additional, Morino, Shun, additional, Inaba, Saori, additional, Nakamura, Ayane, additional, Kumagai, Koshi, additional, Wakatsuki, Takeru, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, and Seimiya, Hiroyuki, additional

Published
2024
Full Text
View/download PDF

54. Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

55. Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

56. Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, primary, Sugimoto, Naotoshi, primary, Kawakami, Hisato, primary, Oshima, Takashi, primary, Yamaguchi, Kensei, primary, Hino, Kaori, primary, Hirao, Motohiro, primary, Kurokawa, Yukinori, primary, Kawakami, Takeshi, primary, Tsuda, Masahiro, primary, Hara, Hiroki, primary, Kaname, Shota, primary, Matsuoka, Daiko, primary, Otake, Yohei, primary, Yasuda, Keisuke, primary, Takase, Takao, primary, Takashima, Shuya, primary, Semba, Taro, primary, and Muro, Kei, primary

Published
2024
Full Text
View/download PDF

60. ASO Visual Abstract: Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

Author

Yoshino, Koichiro, Osumi, Hiroki, Ito, Hiromichi, Kamiimabeppu, Daisaku, Ooki, Akira, Wakatsuki, Takeru, Shimozaki, Keitaro, Nakayama, Izuma, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Oba, Atsushi, Ono, Yoshihiro, Sato, Takafumi, Inoue, Yosuke, Takahashi, Yu, Yamaguchi, Kensei, and Shinozaki, Eiji

Published
2022
Full Text
View/download PDF

62. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program

Author

Nakamura, Yoshiaki, Yamashita, Riu, Okamoto, Wataru, Komatsu, Yoshito, Yuki, Satoshi, Ueno, Makoto, Kato, Ken, Taniguchi, Hiroya, Kagawa, Yoshinori, Denda, Tadamichi, Hara, Hiroki, Esaki, Taito, Moriwaki, Toshikazu, Sunakawa, Yu, Oki, Eiji, Nagashima, Fumio, Nishina, Tomohiro, Satoh, Taroh, Kawakami, Hisato, Yamaguchi, Kensei, Ohtsubo, Koushiro, Kato, Takeshi, Horita, Yosuke, Tsuji, Akihito, Yasui, Hisateru, Goto, Masahiro, Hamamoto, Yasuo, Wakabayashi, Masashi, Ikeno, Takashi, Shitara, Kohei, Bando, Hideaki, Tsuchihara, Katsuya, Miki, Izumi, Ichiki, Hiroko, Ohtsu, Atsushi, and Yoshino, Takayuki

Published
2023
Full Text
View/download PDF

63. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Author

Janjigian, Yelena Y, Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Shen, Lin, Wyrwicz, Lucjan, Yamaguchi, Kensei, Skoczylas, Tomasz, Campos Bragagnoli, Arinilda, Liu, Tianshu, Schenker, Michael, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V, Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M, Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, and Ajani, Jaffer A

Published
2021
Full Text
View/download PDF

64. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Author

Siena, Salvatore, Di Bartolomeo, Maria, Raghav, Kanwal, Masuishi, Toshiki, Loupakis, Fotios, Kawakami, Hisato, Yamaguchi, Kensei, Nishina, Tomohiro, Fakih, Marwan, Elez, Elena, Rodriguez, Javier, Ciardiello, Fortunato, Komatsu, Yoshito, Esaki, Taito, Chung, Ki, Wainberg, Zev, Sartore-Bianchi, Andrea, Saxena, Kapil, Yamamoto, Eriko, Bako, Emarjola, Okuda, Yasuyuki, Shahidi, Javad, Grothey, Axel, and Yoshino, Takayuki

Published
2021
Full Text
View/download PDF

65. Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

Author

Kato, Takeshi, Kagawa, Yoshinori, Kuboki, Yasutoshi, Gamoh, Makio, Komatsu, Yoshito, Yasui, Hirofumi, Satake, Hironaga, Oki, Eiji, Tanioka, Hiroaki, Kotaka, Masahito, Makiyama, Akitaka, Denda, Tadamichi, Goto, Masahiro, Yoshino, Takayuki, Yamazaki, Kentaro, Soeda, Junpei, Shibuya, Kazunori, Iwata, Masaru, Oba, Koji, and Yamaguchi, Kensei

Published
2021
Full Text
View/download PDF

67. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers

Author

Kobayashi, Kazuo, Sugiyama, Erika, Shinozaki, Eiji, Wakatsuki, Takeru, Tajima, Masataka, Kidokoro, Hiyori, Aoyama, Takeshi, Nakano, Yasuhiro, Kawakami, Kazuyoshi, Hashimoto, Koki, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Chin, Keisho, Nakayama, Izuma, Ooki, Akira, Takahari, Daisuke, Suzuki, Wataru, Yokokawa, Takashi, Minowa, Yuichi, Hiraoka, Tomoko, Suzuki, Kenichi, Sato, Hitoshi, Hama, Toshihiro, and Yamaguchi, Kensei

Published
2021
Full Text
View/download PDF

68. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Author

Kang, Yoon-Koo, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter, Wainberg, Zev, Kang, Yoon-Koo, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, Enzinger, Peter, and Wainberg, Zev

Abstract

BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. RESULTS: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. CONCLUSIONS: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626). CLINICAL TRIAL REGISTRATION: NCT03694522.

Published
2024

69. Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer.

Author

Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Dan, Shingo, Seimiya, Hiroyuki, and Yamaguchi, Kensei

Subjects
THERAPEUTIC use of antineoplastic agents, PROTEIN kinase inhibitors, PREDICTIVE tests, RESEARCH funding, ENZYME-linked immunosorbent assay, ANTINEOPLASTIC agents, TUMOR markers, COLORECTAL cancer, METASTASIS, TRANSLATIONAL research, CELL lines, GENE expression, MATRIX metalloproteinases, DRUG efficacy, RESEARCH, RESEARCH methodology, PROGRESSION-free survival, DISEASE progression, OVERALL survival, CHEMICAL inhibitors
Abstract

Simple Summary: Regorafenib offers longer survival for patients with refractory metastatic colorectal cancer (mCRC). We aimed to identify biomarkers for regorafenib through preclinical and translational studies. In silico analysis identified matrix metalloproteinase (MMP)-14 and MMP-9 as key biomarkers. Validation in patients receiving regorafenib or FTD/TPI showed that high MMP-14 levels were correlated with a better response to regorafenib. Additionally, lower MMP-9 levels before the second cycle were linked to improved disease control and survival. These findings suggest that MMP-14 and MMP-9 could serve as prognostic markers for regorafenib efficacy. In identifying biomarkers for anticancer drugs, the lack of objectivity in selecting candidate factors makes interpretation difficult. We performed preclinical analysis and a translational validation study to identify candidate biomarkers for regorafenib efficacy in metastatic colorectal cancer (mCRC). Using in silico COMPARE analysis with a human cancer cell line panel, JFCR39, we selected candidate biomarkers whose expression correlates with regorafenib sensitivity. We validated predictive values in mCRC patients receiving regorafenib (discovery, n = 53) and FTD/TPI (control, n = 16). Blood samples were obtained at baseline (BL), before the second cycle (2nd), and at progressive disease (PD), and biomarker levels were measured using ELISA. Our analysis showed that high matrix metalloproteinase (MMP)-14 expression was associated with a high sensitivity to regorafenib. In the discovery cohort, high MMP-14 levels at BL and PD were correlated with tumor shrinkage and longer progression-free survival (PFS). A subsequent analysis of other related factors further indicated that the patients with decreased MMP-9 levels at the 2nd had higher disease control rates, tumor shrinkage, longer PFS, and overall survival than those with increased changes. These findings were not observed in the control cohort. Our study suggests MMP-14 and MMP-9 may serve as prognostic markers for regorafenib and provide insights into novel combination therapies with anti-MMP-9 agents or FTD/TPI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

70. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Author

Janjigian, Yelena Y., Ajani, Jaffer A., Moehler, Markus, Shen, Lin, Garrido, Marcelo, Gallardo, Carlos, Wyrwicz, Lucjan, Yamaguchi, Kensei, Cleary, James M., Elimova, Elena, Karamouzis, Michalis, Bruges, Ricardo, Skoczylas, Tomasz, Bragagnoli, Arinilda, Liu, Tianshi, Tehfe, Mustapha, Zander, Thomas, Kowalyszyn, Ruben, Pazo-Cid, Roberto, and Schenker, Michael

Published
2024
Full Text
View/download PDF

71. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer

Author

Kotani, Daisuke, Bando, Hideaki, Taniguchi, Hiroya, Masuishi, Toshiki, Komatsu, Yoshito, Yamaguchi, Kensei, Nakajima, Takako, Satoh, Taroh, Nishina, Tomohiro, Esaki, Taito, Nomura, Shogo, Takahashi, Koji, Iida, Shinobu, Matsuda, Seiko, Motonaga, Shinya, Fuse, Nozomu, Sato, Akihiro, Fujii, Satoshi, Ohtsu, Atsushi, Ebi, Hiromichi, and Yoshino, Takayuki

Published
2020
Full Text
View/download PDF

73. Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Author

Kawazoe, Akihito, primary, Yamamoto, Noboru, additional, Sugimoto, Naotoshi, additional, Kawakami, Hisato, additional, Oshima, Takashi, additional, Yamaguchi, Kensei, additional, Hino, Kaori, additional, Hirao, Motohiro, additional, Kurokawa, Yukinori, additional, Kawakami, Takeshi, additional, Tsuda, Masahiro, additional, Hara, Hiroki, additional, Kaname, Shota, additional, Matsuoka, Daiko, additional, Otake, Yohei, additional, Yasuda, Keisuke, additional, Takase, Takao, additional, Takashima, Shuya, additional, Semba, Taro, additional, and Muro, Kei, additional

Published
2024
Full Text
View/download PDF

74. Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

Author

Shah, Manish A., primary, Shitara, Kohei, additional, Lonardi, Sara, additional, Chao, Yee, additional, Yamaguchi, Kensei, additional, Kukielka-Budny, Bozena, additional, Ryu, Min-Hee, additional, Ungureanu, Andrei, additional, Oh, Mok, additional, Chang, Lawrence, additional, Yang, Hongbo, additional, Chai, Xinglei, additional, Bhattacharya, Pranob P., additional, Matsangou, Maria, additional, Ranganath, Radhika, additional, Ajani, Jaffer A., additional, and Xu, Rui-Hua, additional

Published
2024
Full Text
View/download PDF

75. Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.

Author

Tamba, Mikako, primary, Osumi, Hiroki, additional, Fukuoka, Shota, additional, Ogura, Mariko, additional, Okamura, Akihiko, additional, Kanamori, Jun, additional, Imamura, Yu, additional, Takahari, Daisuke, additional, Yoshino, Koichiro, additional, Udagawa, Shohei, additional, Wakatsuki, Takeru, additional, Shinozaki, Eiji, additional, Watanabe, Masayuki, additional, Yamaguchi, Kensei, additional, Chin, Keisho, additional, and Ooki, Akira, additional

Published
2024
Full Text
View/download PDF

76. Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.

Author

Shimozaki, Keitaro, primary, Nakayama, Izuma, additional, Takahari, Daisuke, additional, Nagashima, Kengo, additional, Yoshino, Koichiro, additional, Fukuda, Koshiro, additional, Fukuoka, Shota, additional, Osumi, Hiroki, additional, Ogura, Mariko, additional, Wakatsuki, Takeru, additional, Ooki, Akira, additional, Shinozaki, Eiji, additional, Chin, Keisho, additional, and Yamaguchi, Kensei, additional

Published
2024
Full Text
View/download PDF

77. A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Author

Kotani, Daisuke, primary, Yamaguchi, Kensei, additional, Kato, Ken, additional, Hara, Hiroki, additional, Miura, Akinori, additional, Satoh, Taroh, additional, Komine, Keigo, additional, Kunisaki, Chikara, additional, Yabusaki, Hiroshi, additional, Hagiwara, Akiko, additional, Suzuki, Noriko, additional, Toyoizumi, Kiichiro, additional, Curtin, Joshua C, additional, Chowdhury, Sanjib, additional, Knoblauch, Roland Elmar, additional, and Doi, Toshihiko, additional

Published
2024
Full Text
View/download PDF

78. Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy.

Author

Aoki, Yu, primary, Nakamura, Yoshiaki, additional, Komatsu, Yoshito, additional, Taniguchi, Hiroya, additional, Sunakawa, Yu, additional, Shiozawa, Manabu, additional, Kitagawa, Chiyoe, additional, Ohta, Takashi, additional, Matsuhashi, Nobuhisa, additional, Yamazaki, Kentaro, additional, Boku, Shogen, additional, Takahashi, Naoki, additional, Esaki, Taito, additional, Kawakami, Hisato, additional, Kagawa, Yoshinori, additional, Nishina, Tomohiro, additional, Yamaguchi, Kensei, additional, Bando, Hideaki, additional, and Yoshino, Takayuki, additional

Published
2024
Full Text
View/download PDF

79. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.

Author

Shitara, Kohei, primary, Moehler, Markus H., additional, Ajani, Jaffer A., additional, Shen, Lin, additional, Garrido, Marcelo, additional, Gallardo, Carlos, additional, Wyrwicz, Lucjan S., additional, Yamaguchi, Kensei, additional, Cleary, James M., additional, Elimova, Elena, additional, Bruges Maya, Ricardo Elias, additional, Karamouzis, Michalis, additional, Skoczylas, Tomasz, additional, Bragagnoli, Arinilda, additional, Liu, Tianshu, additional, Tehfe, Mustapha, additional, Feeney, Kynan, additional, Wang, Rui, additional, Nathani, Raheel, additional, and Janjigian, Yelena Y., additional

Published
2024
Full Text
View/download PDF

80. Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

Author

Udagawa, Shohei, primary, Osumi, Hiroki, additional, Ooki, Akira, additional, Wakatsuki, Takeru, additional, Fukuoka, Shota, additional, Yoshino, Koichiro, additional, Tamba, Mikako, additional, Ogura, Mariko, additional, Takahari, Daisuke, additional, Chin, Keisho, additional, Yamaguchi, Kensei, additional, and Shinozaki, Eiji, additional

Published
2024
Full Text
View/download PDF

81. Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.

Author

Park, Haeseong, primary, Bekaii-Saab, Tanios S., additional, Kim, Sunnie S., additional, Pishvaian, Michael J., additional, Sunakawa, Yu, additional, Kamath, Suneel Deepak, additional, Kawazoe, Akihito, additional, Muro, Kei, additional, Zhen, David Bing, additional, Hirano, Hidekazu, additional, Maestas, Erika, additional, Grierson, Patrick, additional, Sugimoto, Naotoshi, additional, Yamaguchi, Kensei, additional, Ubowski, Michelle, additional, Tan, Qianwen, additional, Adelberg, David E., additional, and Strickler, John H, additional

Published
2024
Full Text
View/download PDF

82. In Vitro Throughput Screening of Anticancer Drugs Using Patient-Derived Cell Lines Cultured on Vascularized Three-Dimensional Stromal Tissues

Author

Takahashi, Yuki, primary, Morimura, Rii, additional, Tsukamoto, Kei, additional, Gomi, Sayaka, additional, Kato, Asuka, additional, Mizukami, Miki, additional, Naito, Yasuyuki, additional, Nagayama, Satoshi, additional, Shinozaki, Eiji, additional, Yamaguchi, Kensei, additional, Fujita, Naoya, additional, Kitano, Shiro, additional, Katayama, Ryohei, additional, and Matsusaki, Michiya, additional

Published
2024
Full Text
View/download PDF

86. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Author

Moehler, Markus, primary, Xiao, Hong, additional, Blum, Steven I., additional, Elimova, Elena, additional, Cella, David, additional, Shitara, Kohei, additional, Ajani, Jaffer A., additional, Janjigian, Yelena Y., additional, Garrido, Marcelo, additional, Shen, Lin, additional, Yamaguchi, Kensei, additional, Liu, Tianshu, additional, Schenker, Michael, additional, Kowalyszyn, Ruben, additional, Bragagnoli, Arinilda Campos, additional, Bruges, Ricardo, additional, Montesarchio, Vincenzo, additional, Pazo-Cid, Roberto, additional, Hunter, Shannon, additional, Davenport, Eric, additional, Wang, Jinyi, additional, Kondo, Kaoru, additional, Li, Mingshun, additional, and Wyrwicz, Lucjan, additional

Published
2023
Full Text
View/download PDF

87. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Author

Nakamura, Yoshiaki, Taniguchi, Hiroya, Ikeda, Masafumi, Bando, Hideaki, Kato, Ken, Morizane, Chigusa, Esaki, Taito, Komatsu, Yoshito, Kawamoto, Yasuyuki, Takahashi, Naoki, Ueno, Makoto, Kagawa, Yoshinori, Nishina, Tomohiro, Kato, Takeshi, Yamamoto, Yoshiyuki, Furuse, Junji, Denda, Tadamichi, Kawakami, Hisato, Oki, Eiji, Nakajima, Takako, Nishida, Naohiro, Yamaguchi, Kensei, Yasui, Hisateru, Goto, Masahiro, Matsuhashi, Nobuhisa, Ohtsubo, Koushiro, Yamazaki, Kentaro, Tsuji, Akihito, Okamoto, Wataru, Tsuchihara, Katsuya, Yamanaka, Takeharu, Miki, Izumi, Sakamoto, Yasutoshi, Ichiki, Hiroko, Hata, Masayuki, Yamashita, Riu, Ohtsu, Atsushi, Odegaard, Justin I., and Yoshino, Takayuki

Published
2020
Full Text
View/download PDF

90. Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G)

Author

Nakajima, Takako Eguchi, Yamaguchi, Kensei, Boku, Narikazu, Hyodo, Ichinosuke, Mizusawa, Junki, Hara, Hiroki, Nishina, Tomohiro, Sakamoto, Takeshi, Shitara, Kohei, Shinozaki, Katsunori, Katayama, Hiroshi, Nakamura, Shinichiro, Muro, Kei, and Terashima, Masanori

Published
2020
Full Text
View/download PDF

95. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, and Shah, Manish A

Published
2019
Full Text
View/download PDF

96. Cetuximab every 2 weeks versus standard weekly dosing administration schedule.

Author

Bokemeyer, Carsten, Ciardiello, Fortunato, Dubreuil, Olivier, Guigay, Joel, Kasper, Stefan, Pfeiffer, Per, Pinto, Carmine, Yamaguchi, Kensei, Yoshino, Takayuki, Zielinski, Christoph, Esser, Regina, and Tabernero, Josep

Abstract

Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence. Cetuximab is a drug for patients with colorectal cancer or cancer of the head and neck. It is usually administered once a week. However, studies have shown that cetuximab given once every 2 weeks instead has similar clinical benefits and side effects. Based on this evidence, the every 2 weeks dosing schedule has been approved for use in USA and Japan. The every 2 weeks dosing schedule is a convenient alternative to the weekly schedule. It may result in fewer hospital visits, improved patient quality of life, reduced healthcare costs and more flexibility for medical staff. This review summarizes the current evidence and benefits for the every 2 weeks dosing schedule. A review highlights comparable pharmacokinetics, efficacy and safety data reported for #cetuximab #every2weeks and weekly dosing schedules. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

97. Exploratory Analysis of Serum HER2 Extracellular Domain for HER2 Positive Gastric Cancer Treated with SOX plus Trastuzumab

Author

Wakatsuki, Takeru, primary, Ishizuka, Naoki, additional, Hironaka, Shuichi, additional, Minashi, Keiko, additional, Kadowaki, shigenori, additional, Goto, Masanori, additional, Shoji, Hirokazu, additional, Hirano, Hidekazu, additional, Nakayama, Izuma, additional, Osumi, Hiroki, additional, Ogura, Mariko, additional, Chin, Keisho, additional, Yamaguchi, Kensei, additional, and Takahari, Daisuke, additional

Published
2023
Full Text
View/download PDF

98. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

Author

Chen, Mingjue, primary, Mashima, Tetsuo, additional, Oishi, Taichi, additional, Muramatsu, Yukiko, additional, Seto, Yosuke, additional, Takamatsu, Manabu, additional, Kawata, Naomi, additional, Morino, Shun, additional, Nakamura, Ayane, additional, Inaba, Saori, additional, Yuan, Xunmei, additional, Maruyama, Kohei, additional, Suzuki, Mai, additional, Sato, Ayana, additional, Yoshida, Haruka, additional, Jang, Myung-Kyu, additional, Mizutani, Anna, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, Shirai, Fumiyuki, additional, Nagayama, Satoshi, additional, Katayama, Ryohei, additional, and Seimiya, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

99. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study

Author

Shitara, Kohei, primary, Yamaguchi, Kensei, additional, Muro, Kei, additional, Yasui, Hisateru, additional, Sakai, Daisuke, additional, Oshima, Takashi, additional, Fujimura, Masahiro, additional, Sato, Yuta, additional, Yamazaki, Shunsuke, additional, Wakabayashi, Tatsuya, additional, Sugihara, Masahiro, additional, Kamio, Takahiro, additional, and Shoji, Hirokazu, additional

Published
2023
Full Text
View/download PDF

100. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Rha, Sun Young, primary, Oh, Do-Youn, additional, Yañez, Patricio, additional, Bai, Yuxian, additional, Ryu, Min-Hee, additional, Lee, Jeeyun, additional, Rivera, Fernando, additional, Alves, Gustavo Vasconcelos, additional, Garrido, Marcelo, additional, Shiu, Kai-Keen, additional, Fernández, Manuel González, additional, Li, Jin, additional, Lowery, Maeve A, additional, Çil, Timuçin, additional, Cruz, Felipe Melo, additional, Qin, Shukui, additional, Luo, Suxia, additional, Pan, Hongming, additional, Wainberg, Zev A, additional, Yin, Lina, additional, Bordia, Sonal, additional, Bhagia, Pooja, additional, Wyrwicz, Lucjan S, additional, Mendez, Guillermo, additional, O'Connor, Juan Manuel, additional, Yanzi Castilla, Alvaro, additional, Cundom, Juan, additional, Kaen, Diego, additional, Wong, Rachel, additional, Ng, Weng, additional, Aghmesheh, Morteza, additional, Peressoni, Mauricio, additional, Andrade, Carlos, additional, Franke, Fabio, additional, Alves, Gustavo, additional, Cruz, Felipe Jose, additional, Vianna, Karina, additional, Monteiro, Maria Marcela, additional, Raphael, Michael, additional, Berry, Scott, additional, Jang, Raymond, additional, Tan, Ann, additional, Asselah, Jamil, additional, Yanez Weber, Patricio, additional, Mahave, Mauricio, additional, Sanchez, Cesar, additional, Salman, Pamela, additional, Zhang, Xiaochun, additional, Liu, Tianshu, additional, Lin, Xiaoyan, additional, Yang, Jianwei, additional, Li, Wei, additional, Ying, Jieer, additional, Chen, Xi, additional, Zeng, Shan, additional, Qu, Yanli, additional, Yang, Lin, additional, Zhao, Lin, additional, Chen, Ping, additional, Li, Enxiao, additional, Ye, Feng, additional, Lu, Jianwei, additional, Liang, Xinjun, additional, Zhao, Qun, additional, Yin, Xianli, additional, Li, Junhe, additional, Ling, Yang, additional, Lv, Guoqing, additional, Li, Shouguo, additional, Guerrero, Alvaro, additional, Rubiano, Juan, additional, Gonzalez Fernandez, Manuel, additional, Manneh Kopp, Ray, additional, Guzman Ramirez, Adrian, additional, Corrales, Luis, additional, Gonzalez Herrera, Ileana, additional, Melichar, Bohuslav, additional, Buchler, Tomas, additional, Svoboda, Tomas, additional, Obermannova, Radka, additional, Vrana, David, additional, Cvek, Jakub, additional, Pfeiffer, Per, additional, Baeksgaard, Lene, additional, Yilmaz, Mette, additional, Boige, Valerie, additional, Lopez-Trabada, Daniel, additional, Borg, Christophe, additional, Pannier, Diane, additional, Hiret, Sandrine, additional, Di Fiore, Frederic, additional, Metges, Jean-Philippe, additional, Arnold, Dirk, additional, Martens, Uwe, additional, Lordick, Florian, additional, Stein, Alexander, additional, Castro, Hugo, additional, Lopez, Karla, additional, Ramirez, Julio, additional, Aguilar, Mynor, additional, Chivalan, Marco, additional, Chan, Wendy, additional, Cheng, Ashley, additional, Yeo, Winnie, additional, Arkosy, Peter, additional, Csoszi, Tibor, additional, Hitre, Erika, additional, Horvath, Zsolt, additional, Lowery, Maeve, additional, McDermott, Ray, additional, Morris, Patrick, additional, Hubert, Ayala, additional, Brenner, Baruch, additional, Ben-Aharon, Irit, additional, Shacham-Shmueli, Einat, additional, Man, Sofia, additional, Pelles Avraham, Sharon, additional, Brenner, Ronen, additional, Mishaeli, Moshe, additional, Di Bartolomeo, Maria, additional, Fazio, Nicola, additional, Lonardi, Sara, additional, Garufi, Carlo, additional, Satoh, Taroh, additional, Hara, Hiroki, additional, Iwagami, Shiro, additional, Yasui, Hisateru, additional, Tsuda, Masahiro, additional, Shimoyama, Tatsu, additional, Shoji, Hirokazu, additional, Sugimoto, Naotoshi, additional, Shibata, Nobuhiro, additional, Yamaguchi, Kensei, additional, Amagai, Kenji, additional, Choda, Yasuhiro, additional, Esaki, Taito, additional, Yabusaki, Hiroshi, additional, Oshima, Takashi, additional, Tsuji, Akihito, additional, Kawakami, Hisato, additional, Kawazoe, Akihito, additional, Ishido, Kenji, additional, Kadowaki, Shigenori, additional, Martinez Rodriguez, Jorge, additional, Herrera Martinez, Marytere, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Balancan, Paola, additional, Damianovich, Dragan, additional, Castro Oliden, Victor, additional, Grados, Julio, additional, Torres, Cesar, additional, Wyrwicz, Lucjan, additional, Wysocki, Piotr, additional, Hajac, Lukasz, additional, Zolnierek, Jakub, additional, Karaszewska, Boguslawa, additional, Rha, Sun Young, additional, Orlova, Rashida, additional, Tjulandin, Sergey, additional, Fadeeva, Natalia, additional, Makarycheva, Yulia, additional, Nosov, Dmitry, additional, Smagina, Maria, additional, Chan, Sze, additional, Jacobs, Conrad, additional, Kraus, Peter, additional, Landers, Gregory, additional, Robertson, Barbara, additional, Ruff, Paul, additional, Schoeman, Elizabeth, additional, Maurel, Jean-Marc, additional, Diez Garcia, Marc, additional, Jimenez Fonseca, Paula, additional, Gallego Plazas, Javier, additional, Rivera Herrero, Fernando, additional, Miranda Poma, Jesus, additional, Layos Romero, Laura, additional, Fritsch, Ralph, additional, Bastian, Sara, additional, Winterhalder, Ralph, additional, Dosso, Sara De, additional, Kossler, Thibaud, additional, Yeh, Kun-Huei, additional, Yen, Chia-Jui, additional, Chen, Yen-Yang, additional, Lin, Johnson, additional, Bilici, Mehmet, additional, Ozguroglu, Mustafa, additional, Cil, Timucin, additional, Oksuzoglu, Berna, additional, Harputluoglu, Hakan, additional, Karaoglu, Aziz, additional, Hacibekiroglu, Ilhan, additional, Erdogan, Bulent, additional, Yalcin, Suayib, additional, Adamchuk, Hryhoriy, additional, Bondarenko, Igor, additional, Kolesnik, Oleksii, additional, Ostapenko, Yuriy, additional, Kryzhanivska, Anna, additional, Leshchenko, Lurii, additional, Ilin, Ievgen, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Voitko, Nataliia, additional, Roy, Rajarshi, additional, Young, Anna-Mary, additional, Medley, Louise, additional, Celano, Paul, additional, Overton, Lindsay, additional, Raj, Moses, additional, Dunne, Richard, additional, Wainberg, Zev, additional, Dayyani, Farshid, additional, Larson, Timothy, additional, and Kochenderfer, Mark, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results